Analysts have been eager to weigh in on the Healthcare sector with new ratings on Replimune Group (REPL – Research Report), Minerva Surgical (UTRS – Research Report) and Nektar Therapeutics (NKTR – Research Report).
Replimune Group (REPL)
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Replimune Group on August 26 and set a price target of $33.00. The company’s shares closed last Friday at $19.17.
According to TipRanks.com, Rama is a 3-star analyst with an average return of
Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $43.25, implying a 108.6% upside from current levels. In a report issued on August 16, Piper Sandler also maintained a Buy rating on the stock with a $43.00 price target.
Minerva Surgical (UTRS)
J.P. Morgan analyst Robbie Marcus upgraded Minerva Surgical to Buy yesterday. The company’s shares closed last Friday at $1.77, close to its 52-week low of $1.61.
According to TipRanks.com, Marcus is a 4-star analyst with an average return of
Minerva Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
Nektar Therapeutics (NKTR)
Nektar Therapeutics received a Hold rating from J.P. Morgan analyst Jessica Fye yesterday. The company’s shares closed last Friday at $4.38, close to its 52-week low of $3.02.
According to TipRanks.com, Fye is a 4-star analyst with an average return of
Nektar Therapeutics has an analyst consensus of Hold, with a price target consensus of $4.93.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REPL:
- Analysts’ Top Materials Picks: Ball (BALL), Elanco Animal Health (ELAN)
- Analysts Offer Insights on Consumer Goods Companies: iRobot (IRBT), Foot Locker (FL) and Hyzon Motors (HYZN)
- Analysts Offer Insights on Technology Companies: BAE Systems (OtherBAESF), Marvell (MRVL) and Health Catalyst (HCAT)
- Positive Report for Singular Genomics Systems (OMIC) from J.P. Morgan
- J.P. Morgan upgrades Invitae (NVTA) to a Hold